Antiviral activity of brequinar against foot-and-mouth disease virus infection in vitro and in vivo

[en] Foot-and-mouth disease (FMD) is one of the most highly contagious animal disease that affects cloven-hoofed animals. However, the FMD vaccine does not provide effective protection until adaptive immune protection elicited by the vaccination occurs. Therefore, an alternative application of antiviral agents for inhibition of the FMD virus (FMDV) is needed. Here, we demonstrated that brequinar could exhibit antiviral activity in swine kidney cells (IBRS-2 cells) infected with two different FMDV serotypes. Subsequently, in vivo activity of brequinar was confirmed in a mouse model of infection. Specifically, brequinar at a concentration of 50 μg, provided 25% protection for 5 days following FMDV challenge. These results suggested that brequinar could be used as effective antiviral agent against FMD.

Disciplines :

Microbiology

Author, co-author :

Li, Shifang ; Université de Liège - ULiège > FARAH

Gong, Meijiao ; Université de Liège - ULiège > FARAH

Sun, Yuefeng

Shao, JunJun

Zhang, Yongguang

Chang, Huiyun

Language :

English

Title :

Antiviral activity of brequinar against foot-and-mouth disease virus infection in vitro and in vivo

Publication date :

August 2019

Journal title :

Biomedicine and Pharmacotherapy

ISSN :

0753-3322

eISSN :

1950-6007

Publisher :

Elsevier Masson, France

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 11 July 2020

Statistics

Number of views

69 (10 by ULiège)

Number of downloads

67 (9 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Grubman, M.J., Baxt, B., Foot-and-mouth disease. Clin. Microbiol. Rev. 17 (2004), 465–493.
Alexandersen, S., Zhang, Z., Donaldson, A.I., et al. The pathogenesis and diagnosis of foot-and-mouth disease, J. Comp. Pathol. 129 (2003), 1–36.
Moraes, M.P., de Los, S.T., Koster, M., et al. Enhanced antiviral activity against foot-and-mouth disease virus by a combination of type I and II porcine interferons. J. Virol. 81 (2007), 7124–7135.
Diaz-San, S.F., Medina, G.N., Stenfeldt, C., et al. Foot-and-mouth disease vaccines. Vet. Microbiol. 206 (2017), 102–112.
Rudreshappa, A.G., Sanyal, A., Mohapatra, J.K., et al. Emergence of antigenic variants with in serotype A foot and mouth disease virus in India and evaluation of a new vaccine candidate panel. Vet. Microbiol. 158 (2012), 405–409.
Mahapatra, M., Upadhyaya, S., Aviso, S., et al. Selection of vaccine strains for serotype O foot-and-mouth disease viruses (2007-2012) circulating in Southeast Asia, East Asia and Far East. Vaccine. 35 (2017), 7147–7153.
Park, J.H., Requirements for improved vaccines against foot-and-mouth disease epidemics. Clin. Exp. Vaccine. Res. 2 (2013), 8–18.
Schuurman, H.J., Tanner, M., Pally, C., et al. Brequinar and brequinar analogues in rat allo- and xenotransplantation. Transplant. Proc. 30 (1998), 2240–2243.
Makowka, L., Sher, L.S., Cramer, D.V., The development of Brequinar as an immunosuppressive drug for transplantation. Immunol. Rev. 136 (1993), 51–70.
Jaffee, B.D., Jones, E.A., Loveless, S.E., et al. The unique immunosuppressive activity of brequinar sodium. Transplant. Proc. 25 (1993), 19–22.
Chen, S.F., Perrella, F.W., Behrens, D.L., et al. Inhibition of dihydroorotate dehydrogenase activity by brequinar sodium. Cancer. Res. 52 (1992), 3521–3527.
Schnellrath, L.C., Damaso, C.R., Potent antiviral activity of brequinar against the emerging Cantagalo virus in cell culture. Int. J. Antimicrob. Agents. 38 (2011), 435–441.
Qing, M., Zou, G., Wang, Q.Y., et al. Characterization of dengue virus resistance to brequinar in cell culture. Antimicrob. Agents. Chemother. 54 (2010), 3686–3695.
Luthra, P., Naidoo, J., Pietzsch, C.A., et al. Inhibiting pyrimidine biosynthesis impairs Ebola virus replication through depletion of nucleoside pools and activation of innate immune responses. Antiviral. Res. 158 (2018), 288–302.
Wang, Y., Wang, W., Xu, L., et al. Cross Talk between Nucleotide Synthesis Pathways with Cellular Immunity in Constraining Hepatitis E Virus Replication. Antimicrob. Agents. Chemother. 60 (2016), 2834–2848.
Li, S.F., Gong, M.J., Xie, Y.L., et al. A novel type I interferon, interferon alphaomega, shows antiviral activity against foot-and-mouth disease virus in vitro. Microb. Pathog. 127 (2018), 79–84.
Li, S.F., Gong, M.J., Sun, Y.F., et al. In Vitro and in Vivo antiviral activity of Mizoribine against foot-and-mouth disease virus. Molecules, 24, 2019.
Feng, H.H., Zhu, Z.X., Cao, W.J., et al. Foot-and-mouth disease virus induces lysosomal degradation of NME1 to impair p53-regulated interferon-inducible antiviral genes expression. Cell. Death. Dis., 9, 2018, 885.
Sobrino, F., Saiz, M., Jimenez-Clavero, M.A., et al. Foot-and-mouth disease virus: a long known virus, but a current threat. Vet. Res. 32 (2001), 1–30.
Batt, D.G., Petraitis, J.J., Sherk, S.R., et al. Heteroatom- and carbon-linked biphenyl analogs of Brequinar as immunosuppressive agents. Bioorg. Med. Chem. Lett. 8 (1998), 1745–1750.
Wang, Q.Y., Bushell, S., Qing, M., et al. Inhibition of dengue virus through suppression of host pyrimidine biosynthesis. J. Virol. 85 (2011), 6548–6556.
Lucas-Hourani, M., Dauzonne, D., Jorda, P., et al. Inhibition of pyrimidine biosynthesis pathway suppresses viral growth through innate immunity. PLoS. Pathog., 9, 2013, e1003678.
Chung, D.H., Golden, J.E., Adcock, R.S., et al. Discovery of a Broad-Spectrum Antiviral Compound That Inhibits Pyrimidine Biosynthesis and Establishes a Type 1 Interferon-Independent Antiviral State. Antimicrob. Agents. Chemother. 60 (2016), 4552–4562.
Schoggins, J.W., MacDuff, D.A., Imanaka, N., et al. Pan-viral specificity of IFN-induced genes reveals new roles for cGAS in innate immunity. Nature. 505 (2014), 691–695.
Yeo, K.L., Chen, Y.L., Xu, H.Y., et al. Synergistic suppression of dengue virus replication using a combination of nucleoside analogs and nucleoside synthesis inhibitors. Antimicrob. Agents. Chemother. 59 (2015), 2086–2093.